© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 31, 2022
Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.
Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.
SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.
Most adverse events reported were mild or moderate and found in a similar percentage of patients regardless of treatment cohort.
New data suggests there is no connection between ustekinumab and the risk of malignancies.
There are several companies preparing new treatments for recurrent C difficile infections.
There are several potential treatments on the horizon for C difficile infections.
May 26, 2022
At DDW 2022, Dr. Sands highlights the positive findings from the LUCENT-1 study on the efficacy and safety of mirikizumab.
Patients treated with ustekinumab are not at an increased risk of malignancies.
Treating the disease could reduce the risk of patient distress.
IBS Prevalence High Among Veterans
Long-Term Effectiveness of Adalimumab Reported in Patients with Noninfectious Uveitis
Biologic Agents May Reduce Risk of Mental Health Disorders in Some Patients with Psoriasis